Product Overview

hMG 1200iu Injection, marketed under the brand name Menotrophin and manufactured by Sanzyme Biologics (P) Ltd, is a recombinant human menopausal gonadotropin (hMG) preparation indicated for the treatment of female infertility, male hypogonadism, and male infertility. The medication arrives as a sterile lyophilized powder in a single‑use vial that must be reconstituted with sterile water before administration. Each vial provides 1200 International Units (IU) of biologically active hMG, a dosage strength that has been validated in clinical studies for stimulating ovarian folliculogenesis and testicular testosterone production. Pack configurations include 1, 3, or 6 injections per pack, allowing clinicians to tailor treatment duration to individual patient protocols. The product boasts a reliable delivery window of 6 to 15 days, ensuring timely availability for fertility centers and endocrinology practices worldwide.

What is hMG 1200iu Injection (Menotrophin)

hMG, or human menopausal gonadotropin, consists of a purified mixture of follicle‑stimulating hormone (FSH) and luteinizing hormone (LH) activity derived from the urine of post‑menopausal women. The 1200IU label reflects standardized biological activity that corresponds to approximately 75 IU of FSH and 75 IU of LH per vial, though exact ratios may vary between batches. This preparation is chemically identical to native gonadotropins and is recognized by the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) as a reference standard. Clinically, hMG is employed to enhance ovarian stimulation in assisted reproductive technology cycles and to augment endogenous testosterone synthesis in men with documented hypogonadism. For an in‑depth scientific overview, consult the United States National Institutes of Health (NIH) resource on gonadotropin physiology, available at NIH.

Uses and Benefits

The therapeutic applications of hMG 1200iu Injection span both female and male reproductive health. In women, the medication is a cornerstone of controlled ovarian hyperstimulation, increasing the yield of mature oocytes for in‑vitro fertilization and improving implantation probabilities. In men, hMG stimulates Leydig cells to produce testosterone, addressing conditions such as primary testicular failure and secondary hypogonadism that manifest as low sperm count or azoospermia. Clinical investigations have demonstrated testosterone elevations of 30‑50 ng/dL and modest improvements in sperm concentration when hMG is incorporated into male fertility regimens. Beyond reproductive endpoints, the hormone’s anabolic properties have been explored in muscle‑wasting contexts, though such uses remain off‑label and require further research. The product’s consistent biological activity, documented efficacy, and regulatory acceptance across multiple jurisdictions make it a trusted option for physicians seeking reliable endocrine therapy. Additional details can be found on authoritative pharmaceutical sites such as Drugs.com.

How It Works

The mechanism of action for hMG centers on its ability to mimic endogenous gonadotropins secreted by the anterior pituitary. Upon injection, the preparation binds to FSH receptors on ovarian granulosa cells, stimulating aromatase activity and estradiol synthesis, which promotes follicular maturation. Simultaneously, binding to LH receptors on Leydig cells in the testis triggers androgen production, supporting spermatogenesis and testosterone secretion. This dual‑receptor stimulation leads to measurable increases in serum estradiol levels in women and elevated testosterone concentrations in men, both of which sustain downstream reproductive functions. The pharmacokinetic profile features a short plasma half‑life of roughly 1–2 hours; however, the downstream hormonal responses persist for days, allowing for once‑daily or multi‑day dosing schedules. Detailed mechanistic descriptions and metabolism data are accessible through comprehensive pharmaceutical databases such as Drugs.com.

Dosage Guidelines

Dosage of hMG 1200iu Injection is individualized based on patient age, baseline hormonal values, and therapeutic goals. For ovulation induction in women, clinicians typically administer 75–150 IU daily for 3–6 days, initiating treatment on cycle day 3–5 and monitoring follicular growth via transvaginal ultrasound. In male hormone replacement protocols, the recommended dose ranges from 75–225 IU administered two to three times per week, with adjustments guided by serum testosterone measurements obtained every 2–4 weeks. The lyophilized powder must be reconstituted with 1 mL of sterile water for injection, and the resulting solution should be used within 6 hours to preserve potency. Injection sites—commonly the deltoid, abdominal wall, or gluteal region—should be rotated to minimize local irritation. Comprehensive dosing tables and administration tips are available on the patient‑focused MedlinePlus portal, accessible at MedlinePlus.

Side Effects

Adverse reactions associated with hMG 1200iu Injection are generally mild, though they can vary by indication and patient susceptibility. The most commonly reported side effects include pain, redness, or mild swelling at the injection site, as well as transient abdominal bloating resulting from ovarian stimulation. More serious complications, though less frequent, encompass ovarian hyperstimulation syndrome (OHSS), which may present with abdominal distension, ascites, and respiratory distress, necessitating immediate medical evaluation. In men, supraphysiologic testosterone levels can lead to acne, sleep apnea, or increased hematocrit, underscoring the need for regular laboratory monitoring. Rare hypersensitivity reactions such as urticaria or anaphylactic shock have been documented, prompting discontinuation of therapy. Post‑marketing safety data collected by the U.S. Food and Drug Administration (FDA) highlight the importance of adverse‑event reporting and can be reviewed at FDA Safety Reports.

Warnings and Precautions

Contraindications to hMG 1200iu Injection include known hypersensitivity to gonadotropin preparations, active ovarian cysts unrelated to polycystic ovary syndrome, and certain reproductive malignancies. Patients with uncontrolled thyroid disease, severe pelvic inflammatory disease, or a history of thromboembolic disorders should undergo thorough evaluation before initiating treatment. Prior to therapy, baseline hormone panels—encompassing estradiol, LH, FSH, and testosterone—are recommended to establish reference values and to guide dose adjustments. Pregnant or lactating women must avoid use, as the medication may interfere with fetal development and hormonal homeostasis. Concomitant administration of exogenous estrogen or androgen supplements may alter the expected physiological response and often requires dose modification. For the most current prescribing information, consult the official product label or a qualified endocrinologist. Additional regulatory guidance is provided by the NIH Hormone Research Network, accessible via NIH Hormone Portal.

Frequently Asked Questions